TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma

Abstract

This study demonstrates the potential value of pretreatment tumour biopsy as predictors of TACE resistance in HCC.

Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications

“…As such pathologists have to be careful and to consider that a focal CD34 pattern of staining "per se" cannot be taken as a diagnostic proof against malignancy. An accurate pathological and radiological study of nodule vascularization is therefore expected to provide important information on nodule biology, progression and sensitivity to therapy [20].…”

Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP

“…In this case, locoregional therapy, such as transarterial chemoembolization (TACE), is a feasible option, despite its low rate of efficacy and its associated small improvements in survival [5, 6]. One major drawback of TACE is the development of low sensitivity to chemotherapeutic agents [7]. Therefore, it is urgent to identify novel pharmacological strategies for HCC management.…”

Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

“…TACE-resistant tumors showed 71% CD34+ staining and 89% negative VEGF-staining, respectively, with the association CD34 + and VEGF-able to predict TACE resistance with 81% accuracy, 89% sensitivity and 59% specificity. VEGFand CD34 + suggests that these tumors are more resistant to hypoxia because they have already developed a sufficient vascular network (increased CD34) without requiring further neoangio genesis (decreased VEGF) [74]. The effectiveness of this association was validated in an independent series of 28 HCC biopsies from patients subsequently treated with TACE.…”